[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368457-105":59,"doc-detail-368457-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","first-experiences-of-pilot-clinical-studies-on-boron-neutron-capture-therapy-for-recurrent-gastrointestinal-cancers-using-an-intravenous-injection-of-10-bpa","First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA","","Boron neutron capture therapy (BNCT) is presented as a targeted cancer treatment that relies on selective accumulation of 10B compounds in tumor cells, followed by alpha and lithium particle production after thermal neutron irradiation. Clinical use of BNCT for recurrent gastrointestinal cancers remains limited, motivating this first pilot phase I-II evaluation using intravenous boronophenylalanine (10BPA). Four refractory patients were treated at the Kyoto University Research Reactor. Tumor responses included one partial response and three stable disease cases at three months, alongside symptom relief and acceptable dosimetric exposure to normal tissues, supporting feasibility and informing future fractionated and combination approaches.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-experiences-of-pilot-clinical-studies-on-boron-neutron-capture-therapy-for-recurrent-gastrointestinal-cancers-using-an-intravenous-injection-of-10-bpa/368457/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-experiences-of-pilot-clinical-studies-on-boron-neutron-capture-therapy-for-recurrent-gastrointestinal-cancers-using-an-intravenous-injection-of-10-bpa/368457.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the treatment principle of BNCT described in the study?","Question",{"text":113,"@type":114},"BNCT induces targeted tumor cell damage by concentrating 10B compounds in cancer cells and then producing alpha and lithium particles after thermal neutron irradiation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients were enrolled and what were the key tumor response outcomes?",{"text":118,"@type":114},"Four patients with recurrent gastrointestinal cancers were enrolled. One achieved partial response, while three demonstrated stable disease at three months post-treatment.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study report about safety, symptoms, and dosimetric evaluation?",{"text":122,"@type":114},"No severe adverse effects were observed. BNCT alleviated cancer-related symptoms such as pain and nerve compression, and dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368457,1790432830,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","doi: 10.21873/invivo.13948  \nFirst Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA  \nHIRONOBU YANAGIE1,2,3,4,5, SYOJI MARUYAMA1, KAZUYUKI OYAMA6, YASUO ONO7,8, SHINICHI KUROYAMA8, YASUMASA NONAKA9, RYO HATAE8, YOSHITAKA FURUYA10, MINORU SUZUKI11, SHIN‐ICHIRO MASUNAGA11,12,13, YOSHINORI SAKURAI11, NATSUKO KONDO11, HIROKI TANAKA11, AKIRA MARUHASHI11,  \nKOJI ONO14, TAKUMICHI SUGIHARA6 and HIROYUKI TAKAHASHI3,4,15  \nDepartments of 1Surgery, and 6 Radiology, Shin‐Yamate Hospital, Japan Anti‐Tuberculosis Association, Tokyo, Japan; 2 Department of Gastrointestinal Surgery, Keiaikai Kojin Hospital, Iwate, Japan;  \n3 Institute of Engineering Innovation, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan;  \n4Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan;  \n5 Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan;  \n7 Department of Surgical Oncology, Kameda Medical Center, Chiba, Japan;  \n8 Department of Surgery, Fuchinobe General Hospital, Kanagawa, Japan;  \n9 Department of Surgery, Keiaikai Houyo Hospital, Iwate, Japan;  \n10 Department of Surgery, Sodegaura Satsukidai Hospital, Chiba, Japan;  \n11 Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan;  \n12 BNCT Research Center, Organization for Research Promotion, Osaka Metropolitan University, Osaka, Japan;  \n13 Kinshukai, Hanwadaini Senhoku Hospital, Osaka, Japan;  \n14 Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka, Japan;  \n15 Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan  \nAbstract  \nBackground/Aim: Boron neutron capture therapy (BNCT) is a novel treatment that induces targeted tumor cell damage through the selective accumulation of 10B compounds in cancer cells followed by the production of alpha and lithium particles using thermal neutron irradiation. Despite its potential, clinical applications of BNCT for recurrent gastrointestinal cancers remain limited. This study presents the first pilot clinical evaluation of BNCT using intravenous boronophenylalanine (10BPA) for such cancers.  \nCase Reports: Four patients with recurrent gastrointestinal cancers were enrolled in this phase I‑II clinical study. All had tumors refractory to standard treatments, including surgery, chemotherapy, and radiotherapy. BNCT was performed using thermal neutron irradiation at Kyoto University Research Reactor. 10BPA was administered continued  \n✉  \nHironobu Yanagie, MD, Ph.D., Institute of Engineering Innovation, School of Engineering, The University of Tokyo, 2‑11‑16 Yayoi, Bunkyo‑ku, Tokyo 113‑8656, Japan. Tel: +81 358009194, Fax: +81 358009195, e‑[mail: h.yanagie@gmail.com](mail: h.yanagie@gmail.com)  \nReceived January 1, 2025 | Revised February 16, 2025 | Accepted February 17, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2025 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nintravenously at 400 mg/kg, and no severe adverse effects were observed. Tumor responses varied, with one patient achieving partial response and three demonstrating stable disease at three months post‑treatment. Notably, BNCT alleviated cancer‑related symptoms, such as pain and nerve compression, improving patients’ quality of life. Dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues. Conclusion: BNCT is a promising modality for recurrent gastrointestinal cancers, offering symptom relief and potential antitumor effects. Its safety and feasibility were demonstrated in this study. Future research should explore fractionated BNCT and combination therapies wi","cbCaisE0v7XqIPmm","https://ap.wps.com/l/cbCaisE0v7XqIPmm","pdf",23415196,22,"English","# Abstract\n## Background/Aim\n## Case Reports\n## Conclusion\n# Introduction\n## Clinical rationale for BNCT\n## Imaging and 18F-10BPA-PET\n## Pilot clinical study expansion plans","[{\"question\":\"What is the treatment principle of BNCT described in the study?\",\"answer\":\"BNCT induces targeted tumor cell damage by concentrating 10B compounds in cancer cells and then producing alpha and lithium particles after thermal neutron irradiation.\"},{\"question\":\"How many patients were enrolled and what were the key tumor response outcomes?\",\"answer\":\"Four patients with recurrent gastrointestinal cancers were enrolled. One achieved partial response, while three demonstrated stable disease at three months post-treatment.\"},{\"question\":\"What did the study report about safety, symptoms, and dosimetric evaluation?\",\"answer\":\"No severe adverse effects were observed. BNCT alleviated cancer-related symptoms such as pain and nerve compression, and dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues.\"}]","First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA | PDF",1790177044,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b557f222e1850af6a2b23fbff4102ce.webp",983,1301,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24ed0ca5ceace1ff2982c17ffb7ff8b7.webp",982,1299,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/837293b6cc190d8b05a3657aca086851.webp",981,1298,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/094e0eb6b68fb54e3a4ba81fc2069ba1.webp",980,1297]